The levels of miR-130a, known to be implicated in the regulation of cardiac pathology, were progressively increased in HER2+ breast cancer patients with (p < 0.001) or without cardiotoxicity (p < 0.001) during adjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel and trastuzumab [144]. Here, ERBB2 is linked to breast carcinoma.